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Figure S1. Identification of GS as a CRBN-interacting protein, Related to Figure 1 and 
Figure 2. 
(A) Schematic diagram of the SILAC screen for thalidomide-modulated CRBN-interacting 
proteins. We generated a 293T cell line that stably expressed CRBN with a Flag tag appended to 
its amino terminus (FlagCRBN). FlagCRBN cells were grown in medium formulated with 
isotopically light lysine and arginine (light medium) or in medium formulated with isotopically 
heavy lysine and arginine (heavy medium). Cells growing in heavy medium were treated with 50 
µM thalidomide for 4 h, whereas cells growing in light medium were treated with DMSO. 
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 FlagCRBN immunoprecipitates were prepared in parallel, mixed, and analyzed by quantitative 
mass spectrometry. 
(B) Validation of mass spectrometry. 293T cells stably expressing FlagCRBN (lanes 2–4) were 
treated with 50 µM thalidomide (lane 3) or 10 µM MG132 (lane 4) for 4 h prior to lysis and 
immunoprecipitation (IP) with anti-Flag resin. Immunoprecipitates and input samples were 
fractionated by SDS-PAGE and immunoblotted (IB) with antibodies to detect FlagCRBN and 
endogenous GS, DDB1, and CUL4A.  
(C) Western blot analysis showing input protein levels for in vivo ubiquitylation assay 
corresponding to Figure 1D.  
(D) Confirmation of CRBN depletion. 293T cells were infected with control lentivirus (non-
target shRNA), or lentivirus expressing CRBN shRNA. After 3 weeks of puromycin selection, 
cell extracts were analyzed by SDS-PAGE and immunoblotting with anti-CRBN antibody or 
anti-GAPDH antibody (control). This blot served as a control for Figure 1D. 
(E) Glutamine mediates GS downregulation in multiple cancer cell lines. The indicated cell lines 
were starved of glutamine for 24 h, and then treated with glutamine (4 mM) for 10 h. Equal 
amounts of protein extracts were analyzed by immunoblotting with the indicated antibodies.  
(F) Titration of glutamine. MCF7, H1299, and MM.1S cells were maintained in complete 
medium containing the indicated glutamine concentrations for 24 h. Protein lysates were 
analyzed by Western blotting with antibodies against GS and GAPDH.  
(G) Purification of recombinant human CUL4A–RBX1. Fractions from the last purification step 
were analyzed by SDS-PAGE and staining with Coomassie Blue. This recombinant CUL4A-
RBX1 was used in the in vitro ubiquitylation assay, shown in Figure 1E.  
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Figure S2. Glutamine-induced degradation of GS requires CRL4CRBN activity, related to 
Figure 2. 
(A-C) MLN4924 inhibits glutamine-induced GS degradation. MM.1S (A), MCF7 (B), and 
H1299 (C) cells were starved of glutamine for 24 h. Then the cells were treated with or without 
CRL inhibitor MLN 4924 (1µM) for 1 h, followed by addition of 4 mM glutamine for the 
indicated times (A) or for 6 h (B-C). Equal amounts of cell extracts were analyzed by SDS-
PAGE and immunoblotting with antibodies against GS and GAPDH. In B and C, the 
GS:GAPDH ratio for each sample was calculated, normalized to untreated cells, and is indicated 
below the bottom panels. 
(D-F) Depletion of CRBN impairs the glutamine-induced degradation of GS. Hep3B (D), 
MM.1S (E), and H1299 (F) cells stably expressing control shRNA or CRBN shRNA were 
starved of glutamine for 48, 24, or 24 h, respectively. Then the cells were treated with 4 mM 
glutamine for the indicated times. Cell extracts were analyzed by SDS-PAGE and 
immunoblotting with antibodies against GS, CRBN, and GAPDH (control). The GS:GAPDH 
ratio, normalized to that of untreated cells, is shown below each set of panels. 
  (G) GS accumulates in unperturbed cells depleted of CRBN. MM.1S cells were transduced with 
lentiviruses that expressed either control (CT) shRNA or CRBN shRNA. Forty-eight hours after 
transduction, cells were lysed, fractionated by SDS-PAGE, and immunoblotted with the 
indicated antibodies.  
(H) Western blot showing the knockout (KO) efficiency by CRISPR gRNA CRBN in Hep3B 
cells. Protein lysates were analyzed by Western blotting with antibodies against CRBN and 
GAPDH. CRBN-KO Hep3B cells (CRBN sgRNA_2) were used in subsequent experiments, 
showed in Figure 2C and Figure S2I. 
(I-K) The mRNA levels of GS remained unchanged in CRBN-depleted cells and glutamine-
treated cells. The expression of GS in Hep3B (I), MM1S (J) and H1299 cells (K), starved of 
glutamine for 24 h followed by addition of 4 mM glutamine at the indicated times, was analyzed 
by quantitative RT-PCR. GS mRNA expression in each sample is normalized to GAPDH mRNA 
level. The relative abundance of GS mRNA levels in CRBN-depleted cells or in glutamine-
treated cells was normalized to that of untreated control cells. The relative GS mRNA level is 
displayed as an average of triplicates of quantitative PCR in each sample, and error bars indicate 
± SD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Conservation of the N-terminal extension of GS in major branches of the 
eukaryotic lineage, related to Figure 3. This is a graphic representation of amino acid sequence 
alignment, generated using WebLogo (http://weblogo.berkeley.edu/logo.cgi) 
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Figure S4. GS is acetylated in vitro and in vivo by p300, related to Figure 3, Figure 4 and 
Figure 5. 
(A) Mutations of putative serine, threonine and tyrosine phosphorylation sites in the N-terminal 
extension of GS do not affect its binding to CRBN. 293T cells stably expressing FlagCRBN were 
transfected with empty vector or plasmids encoding the indicated GS mutants for 48 h. Cell 
extracts were immunoprecipitated with anti-Flag antibody and the precipitated and input 
fractions were evaluated by SDS-PAGE and Western blot analysis with antibodies to the Myc 
and Flag tags. TS2-7A combines T2A, T3A, S4A, S6A, and S7A. TS2-19 combines TS2-7A 
plus S19A. TSYA combines TS2-19 plus Y17A. 
(B) HAUb analysis for Figure 4C. Western blot analysis showing ubiquitylation of input and 
precipitated proteins for the experiment shown in Figure 4C.  
(C) p300 and CBP interact with GS. 293T cells were transfected with the indicated Myc-tagged 
GS and HA-tagged p300 or CPB plasmids. Immunoprecipitation was performed with anti-HA 
and the precipitated and input fractions were analyzed by SDS-PAGE and immunoblotting with 
anti-Myc and anti-HA antibodies. S.E., short exposure. L.E., long exposure. 
(D) GS is acetylated in vitro by p300. In vitro acetylation assay using purified recombinant 
human GS tagged with 6 histidine residues (rGS6xHis) was performed in the absence or presence 
of recombinant HAT domain of p300, followed by Western blot analysis with antibodies against 
acetylated lysine (Ac-Lys) and GS.  
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 (E) Lysines 11 and/or 14 are acetylated. Lysates from CRBN-KO 293FT cells transfected with 
plasmids expressing Myc-tagged wild type GS or its AA mutant (K11A, K14A GS) were 
immunoprecipitated with anti-Myc beads, eluted with Myc peptide, and then analyzed by SDS-
PAGE and immunoblotting with the indicated antibodies.  
(F) Glutamine induces acetylation of endogenous GS. CRBN-KO 293FT cells were starved of 
glutamine for 24 h, then pre-treated with or without 10 µM p300/CBP inhibitor C646 in fetal 
bovine serum-free DMEM medium for 1 h, followed by additional treatment with 4 mM 
glutamine for 2 h. The cell lysates were subjected to immunoprecipitation (IP) by normal IgG or 
GS antibody, followed by SDS-PAGE and immunoblotting of precipitated and input fractions 
with the indicated antibodies.  
(G) Purification of recombinant human GS. Fractions from purification of GS were analyzed by 
SDS-PAGE and staining with Coomassie Blue. This recombinant human GS was used in the in 
vitro acetylation assay, shown in Figure S4D.  
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Figure S5. Identification of GS acetylation sites by mass spectrometry, related to Figure 5. 
Mass spectra of GS peptides containing acetylated K11 (A) or K14 (B). Samples were prepared 
from CRBN-KO 293FT cells transfected with GSFlag and treated with HDAC inhibitors (1 µM 
TSA plus 10 mM NAM) for 12 h. As noted in the Results, we also obtained evidence for 
acetylation at K25, K189, K241, K268, and K291.  However, we were unable to detect a peptide 
doubly acetylated at K11 and K14 even though it should, in theory, be detectable. We do not 
understand the reason for this but we note that singly acetylated peptides were detected at 
stoichiometries of ~0.2%, and so if the frequency of double acetylation is the product of the 
individual frequencies, the doubly acetylated species may be below our limit of detection. 
Alternatively, it is possible that acetylation at both residues is coupled to other covalent 
 modification(s) that generate a peptide of m/z that is not accounted for by our search algorithm. 
We did detect a peptide containing T2 at the N-terminus, that was doubly acetylated on T2 and 
K11. The strongest evidence in support of simultaneous acetylation at K11 and K14 being 
critical is that chemically-synthesized N-terminal peptides bound CRBN tightly only when both 
residues were acetylated. 
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Figure S6. GS residues K11 and K14 each contribute to binding CRBN and subsequent 
ubiquitylation, related to Figure 5 and Figure 6. 
 (A) HDAC inhibitors do not act via reduction of GS mRNA transcript. Hep3B cells were starved 
of glutamine for 48 h, followed by incubation for 7 h with or without 4 mM glutamine in the 
presence or absence of HDAC inhibitors (1 µM TSA plus 10 mM NAM). GS mRNA expression 
was measured by quantitative RT- PCR. Gene expression was normalized to GAPDH mRNA 
level. The relative abundance is displayed as an average of triplicates. Error bars indicate ± SD. 
The results shown are representative of two independent experiments.  
(B) The histone acetyltransferase inhibitor garcinol partially blocks glutamine-induced GS 
degradation. H1299 cells were starved of glutamine for 24 h, and then pretreated with or without 
garcinol (20 µM) for 1 h, followed by 4 mM glutamine treatment for 8 h. Cell lysates were 
analyzed by Western blots (WB) with antibodies against GS and GAPDH. The GS:GAPDH 
ratios, normalized to untreated cells, are shown below the bottom panel. 
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 (C) MLN4924 inhibits glutamine- or HDACi-induced GS degradation. MCF7 cells were starved 
of glutamine for 24 h, and then pretreated with or without MLN4924 (2 µM) for 30 min, 
followed by HDAC inhibitor (2 µM SAHA and 10 mM NAM) and 4 mM glutamine treatment 
for 6 h. Cell lysates were analyzed by WB with antibodies against GS, CRBN, and GAPDH. The 
GS:GAPDH ratios, normalized to untreated cells, are shown below the bottom panel. 
(D) MLN4924 diminishes HDAC inhibitor-induced GS degradation. Hep3B cells were starved 
of glutamine for 48 h. Starved cells were either mock treated or supplemented with HDAC 
inhibitors (1 µM TSA and 10 mM NAM) in the presence or absence of 2 µM MLN4924, as 
indicated, for 1 h, followed by addition of 4 mM glutamine for 7 h. Equal amounts of cell 
extracts were analyzed by WB with antibodies against GS and GAPDH. The GS:GAPDH ratios, 
normalized to untreated cells, are shown below the bottom panel. S.E., short exposure. L.E., long 
exposure. 
(E) K11 and K14 individually contribute to CRBN binding. 293T cells stably expressing 
FlagCRBN were transfected with empty vector or plasmids encoding the indicated GS mutants for 
48 h. Cell extracts were immunoprecipitated with anti-Flag antibody and the precipitated and 
input fractions were analyzed by WB with antibodies against DDB1 and the Myc and Flag tags. 
WT: wild type. RR: K11R, K14R GS. AA: K11A, K14A GS.  
(F) K11 and K14 individually contribute to ubiquitylation. 293T cells were transfected with 
plasmids encoding HAUb and the indicated Myc-tagged GS mutants. After 24 h of transfection, 
the cells were treated with 10 µM MG132 for 4 h, followed by cell lysis, denaturation of the 
lysate proteins, and IP with anti-Myc antibody. The input lysates and bound fractions were 
evaluated by SDS-PAGE and immunoblotting with antibodies against the HA and Myc tags. 
(G) CRBN-H357Y can bind GS N-terminal peptide monoacetylated on K11. Pull-down assays 
were carried out using purified recombinant human FlagCRBN and immobilized GS peptides that 
are not acetylated, acetylated on K11 or K14, or acetylated on both residues, as indicated. Bound 
proteins were analyzed by WB with anti-Flag.  
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Figure  S7. Conservation of the tri-Trp pocket in CRBN and structure of human GS, 
related to Figure 6 and Figure 7.  
(A) The C-terminal domains of CRBN orthologs across animal and plant kingdoms show 100% 
conservation in the pocket formed by tryptophan residues W380, W386 and W400 (Sequence 
319-360 top panel, sequence 361-402 middle panel, sequence 403-442 bottom panel). This is a 
 graphic representation of amino acid sequence alignment, generated using WebLogo 
(http://weblogo.berkeley.edu/logo.cgi). 
(B-C) K11 and K14 participate in a network of electrostatic interactions at the interface between 
adjacent protomers of GS. (B) A GS pentamer is shown with each protomer in a different color 
(PDB#: 2QC8). (C) A network of electrostatic interactions coordinates K11 and K14. Silver and 
yellow indicate two neighboring GS subunits. K11 participates in an inter-molecular interaction 
with D174 of an adjacent protomer and an intra-molecular interaction with D231. K14 is buried 
within a hydrophilic pocket at the pentamer interface formed by the intra-subunit residue 
sidechains R227 and D231, the backbone of F89, and inter-subunit residue sidechains D174 and 
E177. Figure was made using MacPyMol: PyMOL Molecular Graphics System, Version 1.5.0.4 
Schrödinger, LLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table&S1,&related&to&Figure&1.&Changes&in&the&level&of&CRBN&interaction&upon&
thalidomide&treatment.&Ratio&(fold)&represents&mean&ratio&of&the&binding&affinity&of&the&protein&to&CRBN&based&on&the&presense/absense&(+/;)&of&thalidomide&(Thal).&
 
Gene&names&
+/BThal&
Ratio&GLNS&(glutamine&synthetase)& 2.508063449&TCP1& 0.892651756&CCT5& 0.858384639&PDIA6& 0.851535402&CCT6A& 0.848325712&CCT8& 0.836829057&RPS8& 0.818644799&IMPDH2& 0.813783598&RPSA;RPSAP58;LAMR1P15& 0.800547102&RPL27& 0.798727238&GLUD1;GLUD2& 0.793470294&HSP90AB1& 0.789986397&VCP;DKFZp434K0126& 0.77019844&RPS3A& 0.76069131&LUC7L2& 0.757764973&ATP5A1& 0.754135965&CMBL& 0.746345707&HSP90AA1& 0.745441526&STK38& 0.744495026&RPS25& 0.73481289&PRPS1& 0.726353702&HNRNPU;HNRPU& 0.713744524&TRIM21& 0.712479811&C22orf28& 0.710856769&RUVBL1& 0.709889429&TXN& 0.703663751&C11orf84& 0.703209501&RPL26;KRBA2;RPL26L1& 0.697997709&HNRNPM;ORF;HNRPM& 0.697658496&RUVBL2& 0.692702735&RPL35;LOC154880& 0.683910758&KIF11& 0.673725446&C12orf23& 0.671822923&SPIN1& 0.668859796&SNRPN;SNRPB& 0.66049843&SNRPD3& 0.658296855&SRSF3;SFRS3& 0.650957681&
PRPS2& 0.644522087&DDX5;DKFZp686J01190& 0.632144562&BAG2& 0.6302998&CLNS1A& 0.626981496&ATP5B& 0.623583663&RIOK1& 0.618678291&RBM39;DKFZp781C0423;DKFZp686A11192;DKFZp781I1140;DKFZp686C17209& 0.618210651&SNRPD1& 0.616791668&IVNS1ABP& 0.613076831&U2AF2& 0.612315329&SNRPF& 0.60714932&BOLA2& 0.598857168&SF3A3& 0.595900095&HNRNPK;HNRPK& 0.590544635&WDR77& 0.589527623&FUS& 0.580689474&SFRS11;SRSF11& 0.572955238&HNRNPAB& 0.569043974&COMT& 0.548219847&PUF60& 0.547071669&DKFZp686K23100;MATR3;DKFZp686K0542& 0.525988372&PIH1D1& 0.515270413&RBMX;RBMXL1& 0.500368967&HNRNPA2B1& 0.453275527&HNRNPL& 0.439962795&HNRNPC;hCG_1641229;HNRPCL1;HNRNPCL1;LOC440563;LOC649330& 0.422945565&&&&&&
Table&S2,&related&to&Figure&2.!GS&is&highly&transcribed&in&brain,&liver,&kidney,&lung&and&skeletal&
muscle.&GS!mRNA!expression!profile!in!diverse!murine!tissues!reported!at!BioGPS.org.!!!
!
Table&S3,&related&to&Figure&2.&Quantification&of&glutamine&and&glutamate&in&serum&of&wild@
type&(WT)&and&homozygous&mutant&CRBN@/@&(HM)&mice&(concentration&original&serum&
sample).&
&!!sample!ID! mean!±!SD!(ng/mL,!n=3)! Q/E!ratio! ! sample!ID! mean!±!SD!(ng/mL,!n=3)! Q/E!ratio!Q! E! Q! E!WT!1! 97.6!!1.5! 8.9!!0.5! 11.0! ! HM!1! 107.6!!2.4! 6.6!!0.2! 16.2!WT!2! 88.0!!2.0! 6.2!!0.4! 14.3! ! HM!2! 92.0!!6.4! 5.1!!0.5! 18.1!WT!3! 96.4!!0.2! 6.7!!0.2! 14.5! ! HM!3! 112.6!!0.7! 6.0!!0.1! 18.9!WT!4! 93.1!!0.6! 8.1!!0.1! 11.5! ! HM!4! 92.2!!0.5! 5.7!!0.1! 16.2!WT!5! 83.3!!0.8! 7.2!!0.1! 11.7! ! HM!5! 96.0!!0.9! 6.4!!0.2! 15.1!WT!6! 72.1!!0.7! 5.0!!0.2! 14.4! ! HM!6! 117.0!!1.3! 9.8!!0.2! 11.9!!
 Table&S4,&related&to&Figure&5.&Identification&of&lysine&acetylation&sites&on&GSFlag&
isolated&from&CRBN@KO&293FT&cells&by!mass&spectrometry.!The!value!for!the!posterior!error!probability!(PEP)!is!shown.&
&
Positions&of&lysine&residues& PEP&Value&11! 2.78E=44!14! 2.08E=28!25! 1.53E=42!189! 5.25E=42!241! 1.16E=05!268! 0.000177049!291! 1.06E=12!!!!
 Table&S5.&List&of&plasmids&used&in&this&study&with&their&corresponding&Deshaies&
laboratory&database&(RDB)&number.&&
 
 
 !
RDB&#& Plasmid&Name&2910! pCMV6+CRBN+Myc+Flag!2911! pCMV6+GS+Myc+Flag!2915! pCDH+Flag+CRBN!!2916! pCDH+FlagCRBNYW/AA!mut!2918! CRBN_1!shRNA:!V2LHS_226831!2919! CRBN_5!shRNA:!V3LHS_395310!3208! CRBN_2!shRNA:!V2LHS_115329!3209! CRBN_3!shRNA:!V2LHS_224589!3210! CRBN_4!shRNA:!V2LHS_226831!3167! pCMV6+GS+Myc!3168! pCMV6+GS!Myc+K11R/K14!R!mutant!(RR)!3169! pCMV6+GS!Myc+K11A/K14!A!mutant!(AA)!3170! pCMV6+GS!Myc+K11A!mutant!(K11A)!3171! pCMV6+GS!Myc+K14A!mutant!(K14A)!3172! pCMV6+GS!Myc+d1!3173! pCMV6+GS!Myc+d2!3174! pCMV6+GS!Myc+d3!3175! pCMV6+GS!Myc+d4!3176! pCDH+!FHGS!3177! pCDH+!d1FHGS!3178! pCDH+!MycGFP!3179! pCDH+!GS+NWT+MycGFP!3180! pCDH+!GS+NRR+MycGFP!3181! pCDH+Flag+CRBN+!Δ1!3182! pCDH+Flag+CRBN+!Δ2!3183! pCDH+Flag+CRBN+!Δ3!3184! pCDH+Flag+CRBN+!Δ4!3185! pCDH+Flag+CRBN+W386E!3186! pCDH+Flag+CRBN+W400E!3187! pCDH+Flag+CRBN+N351R!3188! pCDH+Flag+CRBN+H357Y!3189! pVL1393+CUL4A!3190! pVL1393+GS+6xHis!!3191! pcDNA3+p300+HA!3192! pcDNA3+CBP+HA!3193! pCMV6+GS+Myc+Flag!K11R/K14R!mutant!!
 Table&S6.&Mammalian&Cell&lines&used&in&this&study&with&their&corresponding&Deshaies&
laboratory&database&(DTC)&number.&&
DTC#& Cell&Line&Name&147! HEK293T!cells!expressing!FlagCRBN!Wild+type!148! CRBN+KDO!293T!!150! MM.1S!151! CRBN+KDO!MM.1S!227! Hep3B!228! shRNA!Control!Hep3B!229! CRBNshRNA_4!Hep3B!!217! CRBNshRNA_5!Hep3B!!164! CRBN+KO!293FT!!231! CRBN+knockout!Hep3B!!232! CRBNshRNA_5!NCI+H1299!!47! NCI+H1299!72! A549!43! ZR+75+1!63! MCF7!64! MDA+MB+231!68! T47D!78! SKBr!50! A172!76! U87!!
 Supplemental Experimental Procedures  
Materials and cell lines 
Thalidomide (Tocris Cookson), lenalidomide (Chem-Pacific), pomalidomide (Selleck 
Chemicals), Trichostatin A and Suberoylanilide hydroxamic acid (SAHA; Vorinostat) from 
Sigma, C646 (a competitive histone acetyltransferase (HAT) p300/CBP inhibitor, Sigma), 
garcinol (a p300 and PCAF histone acetyltransferase inhibitor; Santa Cruz Biotechnology), 
MLN4924 (Pevonedistat) from Active Biochem, MG132 (Millipore), and Bortezomib (LC 
Laboratories) were dissolved in dimethyl sulfoxide (DMSO) at room temperature and were 
stored at −80°C until use. Nicotinamide and Cycloheximide (Sigma) were dissolved in distilled 
water and kept at 4°C and -200C, respectively.  
MM.1S, a human multiple myeloma (MM) cell line was purchased from ATCC (American Type 
Culture Collection, Manassas, VA, USA). Cells were maintained in RPMI-I640 medium 
containing 10% (v/v) heat-inactivated fetal bovine serum (Gibco, Grand Island, NY, USA) 
supplemented with 2 mM glutamine and penicillin-streptomycin. Hep3B cells (ATCC # HB-
8064), NCI-H1299 cells (ATCC# CRL-5803), A549 cells (ATCC# CCL185), ZR-75-1 cells 
(ATCC# CRL-1500), MCF7 cells (ATCC# HTB-22), MDA-MB-231 cells (ATCC# HTB-26), 
T47D cells (ATCC# HTB133), SKBr cells (ATCC# HTB30), A172 cells (ATCC# CRL-1620) 
and U87 cells (ATCC# HTB-14) were purchased from ATCC (American Type Culture 
Collection, Manassas, VA, USA). CRBN-knockout 293FT cells were kindly provided by Prof. 
William Kaelin. HEK–293T cells were purchased from ATCC. Cells were grown in DMEM 
supplemented with 10% FBS, 2 mM glutamine and penicillin-streptomycin. All cell lines were 
checked periodically to ensure they were free of mycoplasma contamination. Cell lines were also 
authenticated by short tandem repeat (STR) DNA profiling analysis by Laragen, Inc. 
 Antibodies 
Anti–Flag (M2, F3165) was from Sigma. Anti–HA (influenza hemagglutinin) (16B12, MMS-
101P) was from Covance. Anti-Myc (9E10) was from Santa Cruz Biotechnology. Anti-DDB1 
(ab21080) was from Abcam. Anti-glutamine synthetase (C-20; sc-6640-R) used for Western blot 
was from Santa Cruz Biotechnology. Anti-glutamine synthetase (8G9;&LF)MA0095)&used for 
immunoprecipitation (IP) was&from&Thermo&Fisher&Scientific. Mouse monoclonal anti-CRBN 
antibody against amino acids 1-18 of human CRBN was described previously (Lopez-Girona et 
al., 2012; Zhu et al., 2011). Anti-CRBN antibody (HPA045910) was from Sigma. Anti-GAPDH 
(MAB374) was from Millipore. Anti-acetylated-lysine antibody (9441s) was from Cell 
Signaling.  
 
Plasmids  
Human CRBN and GS expression vectors pCMV6-CRBN-Myc-Flag and pCMV6-GS-Myc-Flag 
(C-terminal Myc- and Flag-tagged) were purchased from OriGene. pCMV6-GS-Myc was 
generated by introducing a STOP codon between Myc and Flag by using a QuikChange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA). All GS deletions or single-point mutations 
in pCMV6-GS-Myc vectors were generated using Q5 Site-Directed Mutagenesis Kit (New 
England BioLabs). Lentiviral vectors directing expression of wild-type FlagCRBN and its mutants 
were constructed in pCDH-T2AcGFP-MSCV (System Biosciences). Chimeric fusion proteins, 
consisting of the N-terminal region of GS (amino acids 1-25) wild type (GS-NWT) or RR mutant 
(GS-NRR) fused to Myc-tagged GFP, were constructed in pCDH-T2AcGFP-MSCV. All cDNAs 
cloned into mammalian expression vectors and lentiviral expression vectors were confirmed by 
DNA sequencing.  
 Generation of stable cell lines expressing FlagCRBN and its mutants 
The lentiviruses were generated according to the manufacturer's protocol (System Biosciences). 
Briefly, lentiviral plasmids were co-transfected with psPAX2 (packaging plasmid) and pMD.2G 
(enveloping plasmid) into HEK293T cells using Fugene HD (Promega). Virus-containing 
supernatants were harvested at 48 h and 72 h post transfection. The lentiviruses were precipitated 
using PEG-it Virus Precipitation Solution according to the manufacturer's protocol (System 
Biosciences). Infection efficiency was >95% as judged by fluorescence microscopy and CRBN 
expression was confirmed by immunoblot. 
 
Identification of FlagCRBN binding partners by mass spectrometry 
SILAC-labeled cultures of the stable cell lines were grown as described previously (Lee et al., 
2011). Briefly, HEK293T cells, stably expressing FlagCRBN, were cultured in medium 
formulated with isotopically light lysine and arginine (‘light’ medium) or in medium formulated 
with isotopically heavy lysine and arginine (‘heavy’ medium). The cells grown in ‘heavy’ 
medium were treated with thalidomide (a final concentration of 50 µM) for 4 hours, while the 
cells growing in ‘light’ medium were treated with DMSO. SILAC experiments were repeated 
after swapping the SILAC labels in which the cells cultured in ‘light’ and ‘heavy’ medium were 
treated with thalidomide and DMSO, respectively. The FlagCRBN immunoprecipitates were 
prepared, mixed, digested with trypsin, and analyzed by quantitative mass spectrometry (Lee et 
al., 2011). 
Thermo raw files were processed and searched with MaxQuant (v. 1.4.1.2) (Cox and Mann, 
2008; Cox et al., 2011). Trypsin was specified as the digestion enzyme with up to two missed 
cleavages. Protein N-terminal acetylation (+42.0106) and methionine oxidation (+15.9949) were 
 specified as variable modifications. Carbamidomethylation of cysteine (+57.0215) was specified 
as a fixed modification. Arg6 (+6.0138) and Lys8 (+8.0142) were specified as the SILAC labels. 
Requantification and match between runs were enabled. Precursor ion tolerance was 7ppm and 
fragment ion tolerance was 0.5 Da. All human Uniprot (Apweiler et al., 2013) entries were 
searched (148298 sequences, downloaded on 05Dec12) along with a contaminant database 
containing proteins such as keratin and trypsin (247 sequences). Additionally, to determine the 
false discovery rate, a decoy database was constructed by reversing the target database. While no 
minimum score was specified, the protein and peptide level false discovery rates were fixed at 
1% and we required that all proteins reported were identified in both biological replicates by at 
least two peptides. 
Proteins were quantified by first calculating the median of all peptide ratios within each 
biological replicate and then calculating the mean of the two biological replicate ratios. Only 
peptides uniquely assignable to the protein group were used for quantification. Ratios were 
normalized in each biological replicate so that the bait (CRBN) had a ratio of 1. Individual ratio 
measurement error was estimated using pooled variance and overall ratio standard error was 
calculated using bootstrap analysis. P-values were calculated using a z-test where the null 
hypothesis was the protein was unchanged (i.e., had a ratio of 1). Q-values were calculated from 
the p-values using the Storey method for calculating false discovery rates (Storey, 2002). A q-
value of 0.05 was used as a threshold for significance. 
 
Identification of acetylated lysines on GS by mass spectrometry 
Chemicals and Reagents—Sequencing-grade trypsin (V5117) and mass spec-grade Lysyl 
endopeptidase (V1671) were purchased from Promega. Mass spec-grade water (39253), mass 
 spec-grade acetonitrile (34967), and n-dodecyl-β-D-maltoside (89903) were obtained from 
Thermo Scientific. 
Immunoprecipitation— CRBN-KO 293FT cells were transiently transfected with a plasmid 
expressing GSFlag. After 36 hours of transfection, cells were treated with HDAC inhibitors (1 µM 
TSA plus 10 mM NAM) for 12 hours. The cell pellets were lysed in lysis buffer (50 mM 
HEPES, pH 7.5, 70 mM KOAc, 5 mM Mg(OAc)2, 0.2% n-dodecyl-β-D-maltoside) containing 
protease inhibitor (Roche; 04693159001) and HDAC inhibitors (1 µM TSA plus 10 mM NAM) 
for 30 min on a gyrating platform at 4 °C. The lysates were centrifuged at 16,600 x g for 15 min 
to remove cell debris, and the supernatant was incubated with anti-FLAG M2 affinity gel 
(Sigma; A2220) on a gyrating platform for 2 hr at 4 °C. The anti-FLAG M2 affinity gel was 
washed with 20 bed volumes of the lysis buffer three times and then with 100 mM Tris–HCl (pH 
8.5) two times, followed by a 15-min elution with 100 mM Tris–HCl (pH 8.5) containing 10 M 
urea. 
Mass Spectrometric Analysis— Eluted proteins were digested at 37 °C first with Lys-C (200 ng) 
for 4 hr in the elution buffer with 8 M urea, and then with trypsin (200 ng) in the same buffer at 
37°C overnight after diluting the urea concentration to 2 M. Following digestion, the tryptic 
peptides were desalted using Stagetips packed with reversed-phase C18 material (3M; 2215-
C18) and concentrated using a vacuum concentrator. Dried samples were acidified by 0.1% 
formic acid prior to mass spectrometric analysis. All liquid chromatography-mass spectrometry 
experiments were performed using an EASY-nLC 1000 (Thermo Scientific) coupled to Q-
Exactive mass spectrometer (Thermo Scientific) equipped with a home-made nano-electrospray 
ion source. Peptides were separated on a 15-cm reversed phase analytical column (75-µm 
internal diameter) packed in-house with C18 beads (3 µm, 100 Å; Agela technologies) using a 
 160-min gradient from 9.5% to 36.5% acetonitrile in 0.1% formic acid at a flow rate of 350 
nL/min. The mass spectrometer was operated in data-dependent mode to automatically switch 
between full-scan MS and tandem MS acquisition. Survey full scan mass spectra were acquired 
in an Orbitrap (300–1800 m/z) using automated gain control target of 1,000,000 ions and a 
resolution of 70,000. The top twelve most intense ions from the survey scan were isolated with 
automated gain control target of 500,000 ions and a resolution of 35,000. The isolated ions were 
fragmented in the high collision dissociation cell by collisionally-induced dissociation with 27% 
normalized collisional energy and 2 m/z isolation width. Precursor ion charge state screening was 
enabled and all singly-charged and unassigned charge states were rejected. The dynamic 
exclusion list was set with a maximum retention time of 30 sec. 
Data Analysis—The resulting raw data files were searched using MaxQuant (version 1.5.3.8) 
(Cox and Mann, 2008) against the IPI human database (v3.87). The search parameters were Lys-
C and tryptic digestion, maximum of two missed cleavages, fixed carboxyamidomethyl 
modifications of cysteine, variable oxidation of methionine, variable acetylation of lysine, 
variable carbamylation of lysine, variable carbamylation of protein N-termini, and variable 
acetylation of protein N-termini. Mass tolerances for precursor ions were 4.5 ppm and those for 
fragment ions were 20 ppm. 
 
CRBN knockdown 
The lentiviral constructs expressing nontargeting (control, CT) and human CRBN shRNAs 
(CRBN_1 shRNA: V2LHS_226831; CRBN_2 shRNA: V2LHS_115329; CRBN_3; shRNA: 
V2LHS_224589; CRBN_4 shRNA: V3LHS_413798; CRBN_5 shRNA: V3LHS_395310) in the 
pGIPZ lentiviral vector were purchased from Open Biosystems. Five lentiviruses targeting 
 CRBN were screened to identify shRNAs that optimally suppressed CRBN. Virus preparation 
and cell infection were performed according to the manufacturer’s protocol, with minor 
modifications. Briefly, shRNA-encoding plasmids were co-transfected with psPAX2 (packaging 
plasmid) and pMD.2G (enveloping plasmid) into HEK293T cells using Fugene HD (Promega). 
Virus-containing supernatants were harvested at 48 h and 72 h post transfection. The lentiviruses 
were precipitated using PEG-it virus precipitation solution according to the manufacturer's 
protocol (System Biosciences), and target cells were infected in the presence of 8 µg/ml 
polybrene. After 24 hours of transduction, the cells were selected with puromycin (1 µg/ml for 
MM.1S cells, and 2-4 µg/ml for 293T cells, Hep3B cells and H1299 cells) for 2 weeks. 
Knockdown efficiencies were analyzed by immunoblot. 
 
Generation of CRBN knockout Hep3B cells by CRISPR/Cas9 
Two pairs of single-guide RNAs (sgRNAs) (CRBN sgRNA_1 Forward 5’- CAC CGG TGT 
CAA AAT TTA TGA TGT T -3’, CRBN sgRNA_1 Reverse 5’- AAA CAA CAT CAT AAA 
TTT TGA CAC C -3’; CRBN sgRNA_2 Forward 5’- CAC CGA ACC ACC TGC CGC TCC 
TGC C -3’, CRBN sgRNA_2 Reverse 5’- AAA CGG CAG GAG CGG CAG GTG GTT C -3’) 
were designed for targeting the human CRBN genomic locus as previously described (Shalem et 
al., 2014). The annealed oligonucleotide pairs were cloned into a lentiCRISPR vector expressing 
Cas9 (Shalem et al., 2014). Lentiviruses were generated by using a similar protocol described 
above. Infected Hep3B cells were selected with puromycin (3 µg/ml) for 2-3 weeks and tested 
for CRBN expression by immunoblot analysis. 
 
Protein expression and purification of recombinant proteins 
 Human RBX1 cDNA was cloned into pAcG2T baculovirus transfer vector (BD Bioscience) with 
an N-terminal GST tag followed by a TEV cleavage site. Human CUL4A or GLUL-6xHis cDNA 
was cloned into pVL1393 baculovirus transfer vector (BD Bioscience). Baculoviral stocks were 
generated by co-transfecting the transfer vector with the linearized ProGreen helper vector (AB 
Vector). Large-scale viral stocks were created following two rounds of viral amplification. 
Proteins were expressed in Hi-Five cells (Invitrogen). CUL4A-RBX1 was purified on 
glutathione resin followed by digestion with TEV protease and size exclusion chromatography 
(Superdex 200; GE Healthcare). GS-6xHis was purified on Ni-NTA affinity resin, followed by 
size exclusion chromatography (Superdex 200; GE Healthcare). 
 
Immunoblot analysis 
Cells were lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% 
Sodium deoxycholate, 0.1 % SDS, [pH 7.5]) supplemented with complete protease inhibitor  
cocktail (Roche). Lysates were clarified by centrifugation at 13,000 RPM for 10 min. Proteins 
were quantified by the Bradford method (Bio-Rad, Hercules, CA). Equal amounts of protein (10-
40 µg/lane) were separated by SDS-PAGE and transferred to a PVDF membrane. The 
membranes were blotted with the indicated antibodies. Anti-rabbit or anti-mouse antibodies 
conjugated to horseradish peroxidase (Vector Labs) were used as secondary antibodies, and the 
signal was detected using a Super Signal West Pico Substrate kit (Fisher Scientific). 
 
Immunoprecipitation 
Cells were lysed in immunoprecipitation (IP) buffer (10 mM Tris [pH 7.6], 150 mM NaCl, 0.5% 
NP-40) containing a protease inhibitor cocktail, followed by centrifugation at 13,000 RPM for 10 
 min. Proteins were immunoprecipitated with the indicated antibodies for 2-4 hours at 40C, 
followed by incubation with protein G sepharose 4 Fast Flow (GE Healthcare) for 1 hour at 40C. 
After binding, the beads were washed 3x in IP buffer containing 300 mM NaCl (stringent 
washing). Immunoprecipitated proteins were resolved by SDS-PAGE, transferred to a PVDF 
membrane, and analyzed by immunoblotting with the indicated antibodies. 
 
Experimental animals  
The generation and screening of CRBN-knockout (KO) mice were described previously (Lee et 
al., 2013). Wild-type and CRBN-KO mice (background of C57BL/6) were maintained on a 
standard chow diet and water ad libitum in pathogen-free conditions with a 12-hour light-dark 
cycle. All experiments were approved by the Gwangju Institute of Science and Technology 
Animal Care and Use Committee. To detect endogenous GS protein levels, male mice (8 weeks 
old; n=3-4 per group) were fasted for 24 hours and fed 4 hours for refeeding. Protein extracts 
were prepared from various mouse tissues and quantified by the Bradford method (Bio-Rad 
Laboratories). An equal amount of proteins was separated by SDS-PAGE and subjected to 
Western immunoblotting. 
 
Quantification of glutamine (Q) and glutamate (E) in mouse serum by LC-MS/MS  
Q and E in serum of wild-type (WT) and homozygous CRBN-KO (HM) mice were determined 
using isotope dilution (ID) LC-MS/MS. For the accurate and precise quantification of Q and E, 
isotope labeled Q and E (Q*, E*) were used as internal standards. The isotope dilution (ID) 
method is the most effective way to reduce uncertainties throughout the whole experimental 
 procedure since the isotopic analogues exhibit the same chemical properties as those of 
unlabeled compounds, except for molecular mass (Burkitt et al., 2008; Jeong et al., 2011). 
All of standard solutions and internal standard solution were prepared gravimetrically, and 
concentrations were adjusted to Q and E in the working serums. A working internal standard 
solution was prepared gravimetrically from isotope labeled L-glutamine (13C5, 99%; Q*) and L-
glutamate (13C5, 99% and 15N1, 99%; E*) purchased from Cambridge Isotopes Laboratory 
(Andover, MA, USA), and concentrations were adjusted to Q and E in the working serum. 
Standard solutions for calibration curves were also prepared in the manner of gravimetry with L-
glutamine (Q) and L-glutamate (E) obtained from Sigma Aldrich (St. Louis, MO, USA). Serum 
was diluted tenfold with water as a working sample. Twenty-five microliters each of diluted 
serum or standard solution and internal standard solution were gravimetrically added to each 
tube and mixed well. Acetonitrile (200 µL) was added to yield a final concentration of 80% v/v. 
The tubes were sealed and mixed again followed by centrifugation for 20 min at 13,000 rpm. The 
supernatant was evaporated and reconstituted with 200 µL water. The samples were filtered 
through a disposable sample filter, and then injected into the LC-MS/MS system. 
Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis 
was performed using an ACQUITY series UPLC system coupled in-line to a Xevo TQ-S MS 
system (Waters, Massachusetts, USA). Chromatographic separation was performed using a 
KINETEX C18 column (150 mm × 2.1 mm I.D., 2.6 µm particle size; Phenomenex, Torrance, 
CA, USA) connected to a guard column unit (Security Ultra, Phenomenex). Isocratic elution 
with the mobile phase comprised 0.3% (v/v) heptafluorobutyric acid in 10 mM ammonium 
formate was adopted for separation with a flow-rate of 400 µL/min. The total run time was 3 min 
per injection, the sample injection volume was 1 µL, and the column oven temperature was 
 maintained at 40°C. MS measurements of the AAs were performed on a triple-quadrupole mass 
spectrometer equipped with a turbospray source in multiple reaction monitoring (MRM) mode. 
The precursor to product ion transitions that were monitored were as follows: Q; 147.1 > 84.1, 
Q*; 152.1 > 88.0, E; 148.0 > 84.1, E*; 154.1 > 89.0. Source ionization and fragmentation 
parameters were finely tuned by monitoring the MS signal prior to sample analysis. Peaks of 
unlabeled and isotope-labeled compounds were integrated and the ratio of these two areas was 
calculated. The peak area ratios were calculated against the calibration curves derived from 
theoretical concentration and peak area ratio of the standard solutions. 
 
Cycloheximide chase experiments 
Cells were seeded overnight in complete medium in 24-well plates (1×105 cells/well), and then 
treated with 100 µg/ml cycloheximide (CHX). At the indicated times following addition of CHX, 
samples were harvested for immunoblot analysis.  
 
In vivo ubiquitylation assay. 
HEK293T stable cell lines expressing nontarget shRNA (Control, CT) or CRBN shRNAs (a 
combination of CRBN_1 plus CRBN_5) were transiently transfected in 10-cm plates with 
plasmids that expressed FlagGS (6 µg) and HAubiquitin (3 µg). After 30 hrs of transfection, the 
cells were treated with DMSO or MG132 (10 µM) for 3 hours. Then, the cells were lysed in 0.3 
ml denaturing IP lysis buffer (1% SDS, 50 mM Tris, 10 mM DTT, [pH 7.5]) and boiled for 5 
minutes. Subsequently, denatured proteins were diluted 10x in immunoprecipitation buffer and 
immunoprecipitated with anti-Flag resin. IP washing steps were performed using IP lysis buffer 
 supplemented with 0.5 M NaCl. Immunoprecipitated proteins were resolved by SDS-PAGE, 
transferred to a PVDF membrane, and analyzed by immunoblotting.  
 
In vivo acetylation assay 
 CRBN-KO 293FT cells were transiently transfected with indicated plasmids. After 48-hour 
transfection, cells were lysed in RIPA buffer containing a protease inhibitor cocktail, 10 mM 
nicotinamide and 500 nM trichostatin A, and immunoprecipitated with the indicated antibodies. 
Immunoprecipitated proteins were resolved by SDS-PAGE, transferred to a PVDF membrane, 
and analyzed by immunoblotting.  
 
In vitro acetylation assay   
The assays were performed as described previously (Van Nguyen et al., 2012). Briefly, 2 
µg of human recombinant GS6xHis purified from insect cells were mixed with 2 µg p300, HAT 
domain (Catalog #: 14-418, Millipore) in 50 µl acetylation assay buffer (50 mM Tris-Cl pH 8, 
10% glycerol, 10 mM butyric acid, 0.1 mM EDTA, 1 mM DTT and protease inhibitor cocktail) 
supplemented with 100 µM acetyl CoA (Sigma). The mixture was then incubated for 60 min at 
30°C on a rotating platform, followed by addition of 2x SDS-PAGE sample buffer (50 µl), 
separation of proteins by SDS-PAGE, and transfer to a PVDF membrane. Acetylation of GS6xHis 
was detected by antibody specific for acetylated lysines.  
 
RNA extraction and real time PCR assay.  
Total RNA was extracted using the RNeasy Mini Kit from QIAGEN and converted into cDNA 
using Advantage RT-for-PCR Kit (Clontech) according to the protocols described in the 
 handbooks. Quantitative RT-PCR was performed using TaqMan gene expression assay (Applied 
Biosystems) and analyzed on the GeneAmp 7700 sequence detection system (Applied 
Biosystems). Gene expression was normalized to GAPDH mRNA level. The relative abundance 
is shown as an average of triplicates of quantitative PCR in each sample, and error bars indicate 
± SD. Human GAPD (GAPDH) endogenous control (4326317E) and human glutamine 
synthetase (Hs00365928_g1) primers were purchased from Applied Biosystems. 
 
Statistical analysis  
 Data are presented as mean ± one standard deviation (SD); p values were calculated using an 
unpaired two-tailed Student’s t test in the Microsoft Excel software. P > 0.05 was considered to 
be not significant; P < 0.05 and P < 0.01 means significant and very significant, respectively. 
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